| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 35 | 2024 | 121 | 9.360 |
Why?
|
| Phenylthiohydantoin | 20 | 2024 | 48 | 3.790 |
Why?
|
| Prostatic Neoplasms | 29 | 2024 | 1768 | 3.270 |
Why?
|
| Benzamides | 20 | 2024 | 237 | 3.260 |
Why?
|
| Nitriles | 20 | 2024 | 160 | 3.040 |
Why?
|
| Androstenes | 13 | 2024 | 45 | 2.990 |
Why?
|
| Receptors, Glucocorticoid | 7 | 2024 | 131 | 2.600 |
Why?
|
| Receptors, Androgen | 14 | 2024 | 122 | 2.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 2552 | 1.470 |
Why?
|
| Androgen Antagonists | 13 | 2024 | 154 | 1.390 |
Why?
|
| Neoplastic Cells, Circulating | 6 | 2024 | 71 | 1.320 |
Why?
|
| Neoplasm Metastasis | 21 | 2024 | 1108 | 1.310 |
Why?
|
| Antineoplastic Agents | 11 | 2023 | 2412 | 1.160 |
Why?
|
| Androgen Receptor Antagonists | 6 | 2024 | 22 | 1.010 |
Why?
|
| Male | 65 | 2024 | 42254 | 0.910 |
Why?
|
| Food-Drug Interactions | 2 | 2014 | 19 | 0.890 |
Why?
|
| Sulfonamides | 5 | 2019 | 317 | 0.880 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 604 | 0.770 |
Why?
|
| Aged, 80 and over | 26 | 2024 | 6777 | 0.730 |
Why?
|
| Testosterone | 4 | 2021 | 275 | 0.690 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 195 | 0.660 |
Why?
|
| Humans | 72 | 2024 | 89073 | 0.660 |
Why?
|
| Orchiectomy | 4 | 2018 | 72 | 0.650 |
Why?
|
| Quality of Life | 6 | 2024 | 1662 | 0.650 |
Why?
|
| Aged | 37 | 2024 | 19078 | 0.640 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 395 | 0.630 |
Why?
|
| Ascites | 1 | 2018 | 56 | 0.610 |
Why?
|
| Pyrimidines | 5 | 2019 | 372 | 0.600 |
Why?
|
| Food | 1 | 2018 | 89 | 0.590 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2022 | 1265 | 0.590 |
Why?
|
| Prospective Studies | 12 | 2024 | 4273 | 0.580 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 307 | 0.570 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 359 | 0.570 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 65 | 0.560 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 170 | 0.550 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 2553 | 0.530 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2023 | 21 | 0.530 |
Why?
|
| Middle Aged | 32 | 2024 | 25865 | 0.530 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 616 | 0.480 |
Why?
|
| Disease Progression | 7 | 2020 | 1488 | 0.470 |
Why?
|
| Prednisone | 4 | 2022 | 258 | 0.470 |
Why?
|
| Patient Safety | 4 | 2019 | 216 | 0.460 |
Why?
|
| Treatment Outcome | 18 | 2024 | 8203 | 0.450 |
Why?
|
| Immediate-Early Proteins | 2 | 2014 | 165 | 0.450 |
Why?
|
| Carcinoma, Small Cell | 1 | 2014 | 133 | 0.450 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2011 | 67 | 0.450 |
Why?
|
| Dietary Fats | 1 | 2014 | 135 | 0.440 |
Why?
|
| Food Labeling | 1 | 2012 | 8 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 967 | 0.410 |
Why?
|
| Indoles | 1 | 2014 | 312 | 0.410 |
Why?
|
| Neoplasms | 6 | 2023 | 3035 | 0.400 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2024 | 108 | 0.400 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 66 | 0.370 |
Why?
|
| Melanoma | 1 | 2014 | 467 | 0.340 |
Why?
|
| Mice, Nude | 4 | 2017 | 814 | 0.330 |
Why?
|
| Signal Transduction | 9 | 2024 | 3374 | 0.330 |
Why?
|
| Cell Survival | 3 | 2017 | 982 | 0.330 |
Why?
|
| Mifepristone | 2 | 2022 | 33 | 0.320 |
Why?
|
| Hormones | 3 | 2022 | 139 | 0.290 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 77 | 0.290 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1543 | 0.270 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 3000 | 0.260 |
Why?
|
| Homeodomain Proteins | 3 | 2024 | 556 | 0.250 |
Why?
|
| Androgens | 3 | 2023 | 175 | 0.240 |
Why?
|
| Neutropenia | 2 | 2023 | 216 | 0.240 |
Why?
|
| Phthalazines | 1 | 2024 | 45 | 0.240 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.240 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 12 | 0.230 |
Why?
|
| CDC2 Protein Kinase | 1 | 2023 | 46 | 0.220 |
Why?
|
| Radium | 1 | 2023 | 7 | 0.220 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 1194 | 0.210 |
Why?
|
| Capecitabine | 2 | 2024 | 98 | 0.210 |
Why?
|
| Piperazines | 1 | 2024 | 283 | 0.210 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 122 | 0.210 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 635 | 0.200 |
Why?
|
| Dehydroepiandrosterone | 2 | 2020 | 49 | 0.200 |
Why?
|
| Urinary Bladder | 1 | 2024 | 246 | 0.200 |
Why?
|
| Frailty | 1 | 2023 | 76 | 0.200 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2024 | 156 | 0.200 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 1214 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 260 | 0.190 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 19 | 0.190 |
Why?
|
| Abiraterone Acetate | 2 | 2018 | 12 | 0.190 |
Why?
|
| Cell Proliferation | 4 | 2017 | 1650 | 0.190 |
Why?
|
| Castration | 2 | 2012 | 41 | 0.190 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2020 | 18 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2021 | 91 | 0.180 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 401 | 0.180 |
Why?
|
| Glucocorticoids | 2 | 2024 | 357 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1940 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2021 | 125 | 0.180 |
Why?
|
| Organic Chemicals | 1 | 2019 | 34 | 0.170 |
Why?
|
| Pain | 1 | 2022 | 400 | 0.170 |
Why?
|
| Boronic Acids | 1 | 2019 | 56 | 0.170 |
Why?
|
| Oxidoreductases | 1 | 2019 | 112 | 0.170 |
Why?
|
| Animals | 8 | 2024 | 27324 | 0.170 |
Why?
|
| Pyridones | 1 | 2019 | 55 | 0.170 |
Why?
|
| Taxoids | 2 | 2016 | 130 | 0.160 |
Why?
|
| United States | 6 | 2020 | 6957 | 0.160 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 11 | 0.160 |
Why?
|
| Immunoconjugates | 1 | 2019 | 110 | 0.160 |
Why?
|
| Azepines | 1 | 2018 | 25 | 0.160 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 16 | 0.160 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 38 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 192 | 0.160 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 33 | 0.160 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2018 | 20 | 0.160 |
Why?
|
| Singapore | 1 | 2018 | 16 | 0.160 |
Why?
|
| Recurrence | 2 | 2019 | 1140 | 0.160 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 329 | 0.150 |
Why?
|
| Quinolines | 1 | 2018 | 91 | 0.150 |
Why?
|
| Adult | 13 | 2021 | 26508 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 82 | 0.150 |
Why?
|
| Fasting | 1 | 2018 | 163 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 93 | 0.140 |
Why?
|
| Mice | 6 | 2024 | 11742 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 645 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 373 | 0.140 |
Why?
|
| Feasibility Studies | 2 | 2021 | 779 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 244 | 0.140 |
Why?
|
| Prostatectomy | 1 | 2020 | 476 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 200 | 0.140 |
Why?
|
| Quinolones | 1 | 2016 | 60 | 0.140 |
Why?
|
| Combined Modality Therapy | 4 | 2024 | 1710 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 470 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 309 | 0.130 |
Why?
|
| Tissue Array Analysis | 2 | 2018 | 127 | 0.130 |
Why?
|
| Benzodioxoles | 1 | 2015 | 16 | 0.130 |
Why?
|
| Female | 10 | 2021 | 46014 | 0.130 |
Why?
|
| Double-Blind Method | 4 | 2023 | 1715 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 887 | 0.130 |
Why?
|
| Steroid Synthesis Inhibitors | 1 | 2014 | 1 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 435 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 272 | 0.120 |
Why?
|
| Metribolone | 1 | 2014 | 5 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 147 | 0.120 |
Why?
|
| Quinazolines | 1 | 2015 | 221 | 0.120 |
Why?
|
| Benzoates | 1 | 2014 | 33 | 0.120 |
Why?
|
| Proteins | 1 | 2019 | 786 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 595 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 315 | 0.110 |
Why?
|
| Prognosis | 3 | 2018 | 3773 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2014 | 89 | 0.110 |
Why?
|
| Immunoblotting | 1 | 2014 | 273 | 0.110 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 88 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2014 | 216 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 266 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 385 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2014 | 691 | 0.110 |
Why?
|
| RNA Interference | 1 | 2014 | 376 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 876 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 428 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2018 | 669 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1157 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2018 | 1652 | 0.100 |
Why?
|
| Dexamethasone | 1 | 2014 | 344 | 0.100 |
Why?
|
| Indazoles | 3 | 2019 | 67 | 0.100 |
Why?
|
| HEK293 Cells | 1 | 2014 | 638 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 41 | 0.100 |
Why?
|
| G1 Phase | 1 | 2011 | 65 | 0.090 |
Why?
|
| Decision Making | 2 | 2014 | 665 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2014 | 1533 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 159 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1363 | 0.090 |
Why?
|
| Survival Rate | 3 | 2019 | 1889 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2011 | 308 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 415 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2013 | 423 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1715 | 0.080 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 60 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2009 | 30 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2019 | 293 | 0.080 |
Why?
|
| Prostate | 3 | 2018 | 393 | 0.080 |
Why?
|
| Research Design | 1 | 2012 | 597 | 0.080 |
Why?
|
| Nausea | 2 | 2019 | 176 | 0.080 |
Why?
|
| Geriatric Assessment | 2 | 2023 | 182 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1796 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1975 | 0.070 |
Why?
|
| Age Factors | 2 | 2023 | 1867 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2024 | 2291 | 0.060 |
Why?
|
| Rats | 1 | 2011 | 4041 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3657 | 0.060 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 55 | 0.060 |
Why?
|
| Leuprolide | 1 | 2024 | 35 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3443 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 948 | 0.060 |
Why?
|
| Precision Medicine | 2 | 2023 | 410 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2024 | 9003 | 0.060 |
Why?
|
| Scandium | 1 | 2023 | 5 | 0.060 |
Why?
|
| Radioisotopes | 1 | 2023 | 45 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2752 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2021 | 2863 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 161 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2024 | 2011 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2024 | 392 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 204 | 0.050 |
Why?
|
| Cystectomy | 1 | 2024 | 105 | 0.050 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2012 | 16 | 0.050 |
Why?
|
| DNA Repair | 1 | 2024 | 362 | 0.050 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 14 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 2001 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 30 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2022 | 40 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 576 | 0.050 |
Why?
|
| Thyrotoxicosis | 1 | 2001 | 18 | 0.050 |
Why?
|
| Cellular Reprogramming | 1 | 2022 | 41 | 0.050 |
Why?
|
| Purines | 1 | 2022 | 93 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2021 | 24 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 617 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2021 | 41 | 0.050 |
Why?
|
| Keratins | 1 | 2021 | 63 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2021 | 48 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2021 | 36 | 0.050 |
Why?
|
| Time Factors | 2 | 2020 | 5320 | 0.050 |
Why?
|
| Glycolysis | 1 | 2022 | 135 | 0.050 |
Why?
|
| Cell Count | 1 | 2021 | 200 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 45 | 0.050 |
Why?
|
| Prescription Drugs | 1 | 2021 | 36 | 0.050 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 1 | 2001 | 117 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2021 | 245 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 389 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 308 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 578 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1012 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2021 | 471 | 0.040 |
Why?
|
| Steroids | 1 | 2020 | 174 | 0.040 |
Why?
|
| Chicago | 2 | 2015 | 1423 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 287 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 485 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 280 | 0.040 |
Why?
|
| Bradycardia | 1 | 2018 | 40 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 345 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 751 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2347 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2019 | 274 | 0.040 |
Why?
|
| Mitochondria | 1 | 2022 | 553 | 0.040 |
Why?
|
| Vomiting | 1 | 2019 | 194 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 894 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 332 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 1528 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 859 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 5466 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1240 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 740 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 628 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 7 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 682 | 0.030 |
Why?
|
| Ketoconazole | 1 | 2014 | 26 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 108 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 540 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2014 | 147 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2439 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 138 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1487 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 149 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 266 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1401 | 0.030 |
Why?
|
| Mutation | 1 | 2024 | 4132 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 794 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 207 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2612 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 80 | 0.030 |
Why?
|
| Kallikreins | 1 | 2012 | 49 | 0.030 |
Why?
|
| United States Department of Defense | 1 | 2011 | 5 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 848 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 727 | 0.020 |
Why?
|
| Health Status | 1 | 2014 | 370 | 0.020 |
Why?
|
| Contrast Media | 1 | 2016 | 1090 | 0.020 |
Why?
|
| Universities | 1 | 2011 | 146 | 0.020 |
Why?
|
| Fatigue | 1 | 2011 | 179 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 182 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 850 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 771 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 230 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1212 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 620 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 359 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 636 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 688 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 682 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1706 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 125 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 531 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 6289 | 0.020 |
Why?
|
| Cell Death | 1 | 2008 | 262 | 0.020 |
Why?
|
| Cell Division | 1 | 2008 | 696 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 9237 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2008 | 509 | 0.020 |
Why?
|
| Homeostasis | 1 | 2008 | 413 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1149 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2001 | 72 | 0.010 |
Why?
|
| Thyroid Function Tests | 1 | 2001 | 120 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 969 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2001 | 328 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 711 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 3010 | 0.010 |
Why?
|